Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs

Forensic Science Review

Volumn 26, Issue 1, 2014, Pages 54-76

  Gurney, S M R ^a   Scott, K S ^b   Kacinko, S L ^b   Presley, B C ^c,d   Logan, B K ^c,e  

^a DREXEL UNIVERSITY   (United States)

^b ARCADIA UNIVERSITY   (United States)

^c NMS Labs   (United States)

^d Temple University   (United States)

^e The Fredric Rieders Family Renaissance Foundation   (United States)

Author keywords

Designer drugs; Drug toxicity; Synthetic cannabinoids; Synthetic drug scheduling

Indexed keywords

EID: 84892605924     PISSN: 10427201     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. Ahmedzai S, Carlyle D, Calder I., Moran F: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy; Brit J Cancer 48:657; 1983.
2. Alhadi S, Tiwari A, Vohra R., Gerona R, Acharya J, Bilello K: High times, low sats: Diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use; J Med Toxicol 9:199; 2013.
3. Arntson A, Ofsa B, Lancaster D., Simon JR, McMullin M, Logan B: Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens; J Anal Toxicol 37:284; 2013.
4. Atwood BK, Mackie K: CB2: A cannabinoid receptor with an identity crisis; Brit J Pharmacol 160:467; 2010.
5. Aung MM, Griffin G, Huffman J.W., Wu M., Keel C, Yang B, Showalter V.M., Abood ME, Martin BR: Influence of the N-1 alky 1 chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding; Drug Alcohol Depen 60:133; 2000.
6. Banerji S, Deutsch CM, Bronstein AC: Spice ain't so nice; Clin Toxicol Phila 48:632; 2010.
7. Bebarta V,Ramirez S, Varney S: Spice: Anew'iegaf'herbal mixture abused by young active duty military personnel; Subst Abuse 33:191; 2012.
8. Benford D: Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists; Psychosomatics 52:295; 2011.
9. Brents LK, Reichard EE, Zimmerman S.M., Moran JH, Fantegrossi WE, Prather PL: Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity; PLoS ONE 6:e21917; 2011.
10. Buchler I, Hayes M, Hedge S., Hockerman S, Jones D, Kortum S., Rico J, Tenbrink R, Wu K: Indazole derivatives; http://patentscope.wipo.int/search/en/ detail.jsf?docld-WO2009106982&recNum=140&docAn=IB2009000432& queryString=(PA/Pfizer)%20AND%20(IC/C07)%20&maxRec=1750 (Accessed November 15, 2013).
11. Castellanos D, Singh S, Thornton G., Avila M, Moreno A: Synthetic cannabinoid use: A case series of adolescents; J Adolescent Health 49:347; 2011.
12. Cheng Y, Prusoff WH: Relationship between the inhibition constant (Kl) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction; Biochem Pharmacol 22:3099; 1973.
13. Chimalakonda KC, Seely KA, Bratton S.M., Brents LK, Moran CL, Endres GW, James L.P., Hollenberg PF, Prather PL, Radominska-Pandya A, et al.: Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor Ligands; Drug Metab Dispos 40:2174; 2012.
14. Cohen J, Morrison S, Greenberg J., Saidinejad M: Clinical presentation of intoxication due to synthetic cannabinoids; Pediatrics 129:el064; 2012.
15. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, Martin BR: Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities; J Pharmacol Exp Ther 265:218; 1993.
16. Cox A, Daw R, Mason M., Grabenauer M, Pande P, Davis K., Wiley J, Stout P, Thomas B, Huffman J: Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids; J Anal Toxicol 36:293; 2012.
17. Curto-Reyes V., Llames S, Menéndez L, Baamonde A: Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM 1241 in two models of bone cancer-induced pain; Brit J Pharmacol 160:561; 2010.
18. D'Souza D., Sewell R, Ranganathan M: Cannabis and psychosis/ schizophrenia: Human studies; Eur Arch Psy Clin N 259:413; 2009.
19. Di Dalmazi G., Vicennati V, Pasquali R., Pagotto U: The unrelenting fall of the pharmacological treatment of obesity; Endocrine 2013.
20. Donnelly M: K2 Synthetic marijuana use among teenagers and young adults in Missouri; Missouri Department of Health & Senior Services; http://health.mo.gov/emergencies/ert/alertsadvisories/pdf/HAd3-5-2010. pdf(Accessed November 15, 2013).
21. Drenzek C, Geller RJ, Steck A, Arnold J., Lopez G, Gerona R, Edison L: Notes from the Field: Severe Illness Associated with Synthetic Cannabinoid Use - Brunswick, Georgia, 2013; Morbidity and Mortality Weekly Reports; November 22, 2013; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6246a7.htm (Accessed November 29, 2013).
22. Ellsworth H, Stellpflug SJ: Déjà vu, another designer drug: Synthetic cannabinoids; ACEP Toxicol Sect News March, 2011; http//groups.yahoo.com/neo/groups/eastem/ conversations/topics/60 (Accessed November 15, 2013).
23. EMCDDA: Perspectives on Drugs - Synthetic Cannabinoids in Europe; European Monitoring Centre for Drugs and Drug Addiction; May 28, 2013; http://www.emcdda.europa,eu/topics/pods/synthetic-cannabinoids (Accessed November 15, 2013).
24. EMCDDA: Understanding the 'Spice' Phenomenon; European Monitoring Centre for Drugs and Drug Addiction: Lisbon, Portugal; 2009; http://www.emcdda.europa, eu/attachements.cfm/att-80086-EN-EMCDDA- Understanding%20the%20'Spice'%20phenomenon-4Update%2020090813.pdf (Accessed November 15, 2013).
25. Every-Palmer S: Synthetic cannabinoid JWH-018 and psychosis: An explorative study; Drug Alcohol Depen 117:152; 2011.
26. Faircloth J, Khandheria B, Shum S: Case report: Adverse reaction to synthetic marijuana; Am J Addict 21:289; 2012.
27. Felder CC, Joyce KE, Briley E.M., Mansouri J., Mackie K, Blond O, Lai Y., Ma AL, Mitchell RL: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors; Mol Pharmacol 48:443; 1995.
28. Forrester M, Kleinschmidt K, Schwarz E., Young A: Synthetic cannabinoid and marijuana exposures reported to poison centers; Hum Exp Toxicol 31:1006; 2012.
29. Forrester M, Kleinschmidt K, Schwarz E., Young A: Synthetic cannabinoid exposures reported to Texas poison centers; J Addict Dis 30:351; 2011.
30. Frank B, Serpell MG, Hughes J, Matthews JNS, Kapur D: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study; Brit Med.J 336:199; 2008.
31. Gay M: Synthetic marijuana spurs state bans; The New York Times July 10, 2012; http://www.nytimes.com/2010/07/ll/us/1lk2.html?adxnnl=l&adxnnlx= 1354307390-xtDkcfVFnlscaS/xILidnow(Accessed November 15, 2013).
32. Griffin G, Atkinson PJ, Showalter V.M., Martin BR, Abood ME: Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-0-(3- [35S]thio)-triphosphate binding assay in rat cerebellar membranes; J Pharmacol Exp Ther 285:553; 1998.
33. Gunderson E, Haughey H, Alt-Daoud N, Joshi A., Hart C: "Spice" and "K2" herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans; Am J Addict 21:320; 2012.
34. Heath T, Burroughs Z, Thompson J., Tecklenburg F: Acute intoxication caused by a synthetic cannabinoid in two adolescents; J Pediatr Pharmacol Ther 17:177; 2012.
35. Henquet C, Krabbendam L, Spauwen J., Kaplan C, Lieb R, Wittchen, HU, Van Os J: Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people; BMJ 330:11; 2005.
36. Hermanns-Clausen M., Kneisel S, Hutter M., Szabo B, Auwärter V: Acute intoxication by synthetic cannabinoids - Four case reports; Drug Test Anal 5:790; 2013.
37. Hermanns-Clausen M., Kneisel S, Szabo B., Auwärter V: Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings; Addiction 108:534; 2012.
38. Hopkins CY, Gilchrist BL: A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids; J Emerg Med 45:544; 2013.
39. Howlett AC, Breivogel CS, Childers S.R., Deadwyler SA, Hampson RE, Porrino LJ: Cannabinoid physiology and pharmacology: 30 years of progress; Neuropharmacology 47:345; 2004.
40. Hoyte CO, Jacob J, Monte A.A., Al-Jumaan M, Bronstein AC, Heard KJ: A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010; Ann Emerg Med 60:435; 2012.
41. Huffman J, Zengin G, Wu M., Lu J, Hynd G, Bushell K., Thompson A, Bushell S, Tartal C, Hurst D, et al.: Structure-activity relationships for l-alkyl-3-(l-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: Steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists; Bioorg Med Chem 13:89; 2005.
42. Huffman JW, Dai D, Martin B.R., Compton DR: Design, synthesis and pharmacology of cannabimimetic indoles; Bioorg Med Chem Lett 4:563; 1994.
43. Huffman JW, Szklennik PV, Almond A, Bushell K., Selley DE, He H, Cassidy MP, Wiley J.L., Martin BR: 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles; Bioorg Med Chem Lett 15:4110; 2005.
44. Hughes B, Gallegos A, Roumen S: Responding to New Psychoactive Substances; European Monitoring Centre for Drugs and Drug Addiction: Lisbon, Portugal; 2011.
45. Hurst D, Loeffler G, McLay R: Psychosis associated with synthetic cannabinoid agonists: A case series; Am J Psychiatry 168:1119
46. Jankovics P, Vâradi A, Tölgyesi L, Lohner S., Németh-Palotâs J, Balla J: Detection and identification of the new potential synthetic cannabinoids l-pentyl-3-(2-iodobenzoyl)indole and l-pentyl-3-(l-adamantoyl)indole in seized bulk powders in Hungary; Forensic Sci Int 214:27; 2012.
47. Jiang W, Zhang Y, Xiao L., Van Cleemput J, Ji S, Bai G., Zhang X: Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects; J Clin Invest 115:3104; 2005.
48. Jinwala FN, Gupta M: Synthetic cannabis and respiratory depression; J Child Adol Psychop 22:459; 2012.
49. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: The Rise in Teen Marijuana Use Stalls, Synthetic Marijuana Use Levels, and Use of "Bath Salts" Is Very Low (a Monitoring the Future report); http://www. monitoringthefuture.org/data/12data.html (Accessed November 15, 2013).
50. Kikura-Hanajiri R., Uchiyama N, Kawamura M., Ogata J, Goda Y: Prevalence of new designer drugs and their legal status in Japan; Yakugaku Zasshi 133:31; 2013.
51. King J, Singleton N, Howard R: Analogue Controls: An Imperfect Law; UK Drug Policy Commission; http://www. ukdpc.org.uk/pubiication/analogue-controls- an-imperfect-law/(Accessed November 15, 2013).
52. Kuster JE, Stevenson JI, Ward S.J., D'Ambra TE, Haycock DA: Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids; J PharmacolExp Ther 264:1352; 1993.
53. Lapoint J,James L, Moran C,Nelson L, Hoffman R, Moran J: Severe toxicity following synthetic cannabinoid ingestion; Clin Toxicol 49:760; 2011.
54. Little PJ, Compton DR, Johnson M.R., Melvin LS, Martin BR: Pharmacology and stereoselectivity of structurally novel cannabinoids in mice; J Pharmacol Exp Ther 247:1046; 1988.
55. Logan BK: Marijuana and driving impairment; In ElSohly MA (ed): Marijuana and the Cannabinoids, Chap 12; Humana Press: Totowa, NJ; 2007.
56. Logan BK, Reinhold LE, Xu A, Diamond FX: Identification of synthetic cannabinoids in herbal incense blends in the United States; J Forensic Sci 57:1168; 2012.
57. Loschner A, Cihla A, Jalali F., Ghamande S: Diffuse alveolar hemorrhage: Add "greenhouse effect" to the growing list; Chest 140:149A; 2011; http://journal.publications.chestnet. org/article.aspx?articleid-1088295 (Accessed November 15, 2013).
58. Maccarrone M, Valensise H, Bari M., Lazzarin N, Romanini C, Finazzi-Agró A: Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage; Lancet 355:1326; 2000.
59. Makriyannis A, Deng H: Cannabimimetic Indole Derivatives; US patent 7241799; http://www.patentlens.net/patentlens/patents.html?patnums=US- 7241799&language-& (Accessed November 15, 2013).
60. Makriyannis A, Lu D, Khanolkar A., Meng Z: Novel Analgesic and Immunomodulatory Cannabinoids; US Patent 20050239874 Al; www.google.com/patents/ US20050239874 (Accessed November 15, 2013).
61. Matsuda LA, Lolait SJ, Brownstein M.J., Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA; Nature 346:561; 1990.
62. McLaughlin P, Lu D, Winston K., Thakur G, Swezey L, Makriyannis A, Salamone J: Behavioral effects of the novel cannabinoid full agonist AM 411; Pharmacol Biochem Behav 81:7S;2005.
63. McQuade D, Hudson S, Dargan P.I., Wood DM: First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201; Eur J Clin Pharmacol 69:373; 2013.
64. Medical Marijuana: 20 Legal Medical Marijuana States and DC-Laws, Fees, and Possession Limits; ProCon.org: Santa Monica, CA; September 16, 2013; http://medicalmarijuana.procon.org/view.resource.php?'resourceID=000881 (Accessed November 15, 2013).
65. MirA, Obafemi A, Young A, Kane C: Myocardial infarction associated with use of the synthetic cannabinoid K2; Pediatrics 128:e1622; 2011.
66. Müller H., Sperling W, Köhrmann M, Huttner F.B., Kornhuber J., Maler J: The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes; Schizophr Res 118 2010.
67. Murphy TD, Weidenbach KN, Van Houten C, Gerona RR, Moran JH, Kirschner RI, Marraffa JM, Stork CM, Birkhead GS, Newman A, et al.: Acute Kidney Injury Associated with Synthetic Cannabinoid Use - Multiple States, 2012; Centers for Disease Control and Prevention Report 62(6); February 2013.
68. Musshoff F, Madea B, Kernbach-Wighton G, Bicker W., Kneisel S, Hutter M, Auwärter V: Driving under the influence of synthetic cannabinoids ("Spice"): A case series; Int J Legal Med May 1 2013 (DOI: 10.1007/s00414-013-0864-1); http://link.springer.com/10.1007/s00414-013-0864-l (Accessed November 15, 2013).
69. Nakajima J, Takahashi M, Nonaka R., Seto T, Suzuki J, Yoshida M., Kanai C, Hamano T: Identification and quantitation of a benzoylindole (2-methoxyphenyl) (1-pentyl-1 H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1 H-indol-3-yl)-(naphthalene-1-yl) methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays; Forensic Toxicol 29:132; 2011.
70. Nakajima J, Takahashi M, Seto T., Kanai C, Suzuki J, Yoshida M., Hamano T: Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-lH-indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the Internet; Forensic Toxicol 29:95; 2011.
71. Oluwabusi OO, Lobach L, Akhtar U., Youngman B, Ambrosini PJ: Synthetic cannabinoid-induced psychosis: two adolescent cases.; J Child Adol Psychop 22:393; 2012.
72. Pacher P, Bâtkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy; Pharmacol Rev 58:389; 2006.
73. Pant S, Deshmukh A, Dholaria B., Varinder K, Ramavaram S, Ukor M., Teran GA: Spicy seizure; Am J Med Sci 344:67; 2012.
74. Parka B, McPartlandb JM, Glass M: Cannabis, cannabinoids and reproduction; Prostag Leukotr Ess 70:189; 2004.
75. Peglow S, Buchner J, Briscoe G: Synthetic Cannabinoid induced psychosis in a previously nonpsychotic patient; Am J Addict 21:287; 2012.
76. Pertwee R: The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids; Aaps J 7:E625; 2005.
77. Pertwee RG: Pharmacology of cannabinoid CB1 and CB2 receptors; Pharmacol Ther 74:129; 1997.
78. Presley BC, Jansen-Varnum SA, Logan BK: Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings; Forensic Sci Rev 25:27; 2013.
79. Robinson L, Goonawardena A, Pertwee R., Hampson R, Riedel G: The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats; Brit J Pharmacol 151:688; 2007.
80. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M: The endocannabinoid system: physiology and pharmacology; A Icohol Alcoholism 40:2; 2005.
81. Saito T, Namera A, Miura N., Ohta S, Miyazaki S, Osawa M., Inokuchi S: A fatal case of MAM-2201 poisoning; Forensic Toxicol 31:333; 2013.
82. Schmid P, Paria B, Krebsbach R., Schmid H, Dey S: Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation; Proc Natl Acad Sci USA 94:4188; 1997.
83. Schneir AB, Baumbacher T: Convulsions associated with the use of a synthetic cannabinoid product; J Med Toxicol 8:63; 2012.
84. Schneir AB, Cullen J, Ly BT: '"Spice"' girls: Synthetic cannabinoid intoxication; J Emerg Med 40:296; 2011.
85. Seely K, Prather P, James L., Moran J: Marijuana-based drugs: Innovative therapeutics or designer drugs of abuse? Mol Interv 11:37; 2011.
86. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D., Pessègue B, Bonnin-Cabanne O, Le Fur G, Caput D, Ferrara P: Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor; Biochim Biophys Acta 1307:132; 1996.
87. Showalter VM, Compton DR, Martin B.R., Abood ME: Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2)>: Identification of cannabinoid receptor subtype selective ligands; J Pharmacol Exp Ther 278:989; 1996.
88. Simmons J, Cookman L, Kang C., Skinner C: Three cases of "spice" exposure; Clin Toxicol 49:431; 2011.
89. Slipetz DM, O'Neill GP, Favreau L, Dufresne C., Gallant M, Guay D, Labelle M., Metters KM: Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase; Mol Pharmacol 48:352; 1995.
90. Sobolevsky T, Prasolov I, Rodchenkov G: Detection of JWH-018 metabolites in smoking mixture post-administration urine; Forensic Sci Int 200:141; 2010.
91. Sontineni SP, Chaudhary S, Sontineni V., Lanspa SJ: Cannabinoid hyperemesis syndrome: Clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse; World J Gastroenterol 15:1264; 2009.
92. Sumnall HR, Evans-Brown M, McVeigh J: Social, policy, and public health perspectives on new psychoactive substances; Drug Test Anal 3:515; 2011.
93. Sun X, Dey S: Endocannabinoid signaling in female reproduction; ACS Chem Neurosci 3:349; 2012.
94. Tacklind J,MacDonald R,Rutks I,Wilt T: Serenoa repens for benign prostatic hyperplasia; Cochrane Database Syst Rev (DOI: 10.1002/14651858. CD001423.pub2); http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090655/ (Accessed November 15, 2013).
95. Tashkin D: Pulmonaryc complications of smoked substance Abuse; Western J Med 5:525; 1990.
96. Teske J, Weiler J-P, Fieguth A, Rothämel T, Schulz Y.,Tröger HD: Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-l-yl-(l-pentylindol-3-yl) methanone (JWH-018) in human serum by liquid chroma-tography-tandem mass spectrometry; J Chromatogr B 878: 2659; 2010.
97. Thornton SL, Wood C, Friesen M.W., Gerona RR: Synthetic cannabinoid use associated with acute kidney injury; Clin Toxicol 51:189; 2013.
98. Tofighi B, Lee JD: Internet highs - Seizures after consumption of synthetic cannabinoids purchased online; J Addict Med 6:240; 2012.
99. Tung CK, Chiang TP, Lam M: Acute mental disturbance caused by synthetic cannabinoid: A potential emerging substance of abuse in Hong Kong; East Asian Arch Psychiatry 22:31;2012.
100. Turu G, Hunyady L: Signal transduction of the CB1 cannabinoid receptor; J Mol Endocrinol 44:75; 2009.
101. UK Home Office: A change to the Misuse of Drugs Act 1971: Control of GBL, 1, 4-BD, BZPand related piperazine compounds, a further group of anabolic steroids and 2 non-steroidal agents, synthetic cannabinoid receptor agonists and oripavine; Home Office Circular 21; 2009; https://www.gov.uk/governtnent/ uploads/system/uploads/attachment-data/file/100526/2l-2009.pdf (Accessed November 15, 2013).
102. US Center for Disease Control and Prevention: Acute Kidney Injury Associated with Synthetic Cannabinoid Use - Multiple States; Morbidity and Mortality Weekly Report; February 15, 2013; http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm6206al.htm (Accessed November 15, 2013).
103. US Food and Drug Administration Safety and Innovation Act; S. e3187 2012; http://www.gpo.gov/fdsys/pkg/BlLLS-112s3187enr/pdf/BILLS-112s3187enr.pdf (Accessed November 15, 2013).
104. Van der Veer N, Friday J: Persistent psychosis following the use of Spice; Schizophr Res 130:285; 2011.
105. Vandrey R, Dunn KE, Fry J.A., Girling ER: A survey study to characterize use of Spice products (synthetic cannabinoids); Drug Alcohol Depen 120:238; 2012.
106. Vardakou I, Pistos C, Spiliopoulou C: Spice drugs as a new trend: mode of action, identification and legislation; Toxicol Lett 197:157; 2010.
107. Vearrier D, Osterhoudt KC: A teenager with agitation higher than she should have climbed; PediatrEmerg Care 26:462; 2010.
108. Washington State Liquor Control Board: 1-502 Implementation; http://www.liq.wa.gov/marijuana/I-502 (Accessed November 15, 2013).
109. Weissman A, Milne GM, Melvin LS Jr: Cannabimimetic activity from CP-47, 497, a derivative of 3-phenylcyclo-hexanol; J Pharmacol Exp Ther 223:516; 1982.
110. WikiProject Colorado: Colorado Marijuana Legalization Initiative, Amendment 64 (2012); Ballotpedia Lucy Burns Institute: Madison, WI; http://ballotpedia.org/wiki/index.php/Colorado-Marijuana-Legalization- Initiative,-Amendment-64-(2012) (Accessed November 15, 2013).
111. Wiley J, Compton D, Dai D., Lainton J, Phillips M, Huffman J., Martin B: Structure-activity relationships of indole- and pyrrole-derived cannabinoids; J Pharmacol Exp Ther 285:995; 1998.
112. Wiley JL, Marusich JA, Lefever T.W., Grabenauer M., Moore KN, Thomas BF: Cannabinoids in disguise: A(9)-Tetrahydrocannabinol-like effects of tetramethyl-cyclopropyl ketone indoles; Neuropharmacology 75C: 145; 2013.
113. Wiley JL, Marusich JA, Martin B.R., Huffman JW: l-Pentyl-3- phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice; Drug Alcohol Depen 123:148; 2012.
114. Wiley JL, Smith VJ, Chen J, Martin B.R., Huffman JW: Synthesis and pharmacology of l-alkyl-3-(l-naphthoyl) indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents; BioorgMedChem 20:2067; 2012.
115. Wintermeyer A, Möller I, Thevis M., Jiibner M, Beike J, Rothschild M.A., Bender K: In vitro phase I metabolism of the synthetic cannabimimetic JWH-018; Anal Bioanal Chem 398:2141; 2010.
116. Yeakel JK, Logan BK: Blood synthetic cannabinoid concentrations in cases of suspected impaired driving; J Anal Toxicol 2013.
117. Young AC, Schwarz E, Medina G., Obafemi A, Feng SY, Kane C, Kleinschmidt K: Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation; Am J Emerg Med 30:e5; 2012.
118. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees J.A., Spanagel R., Schulz K: Withdrawal phenomena and dependence syndrome after the consumption of "Spice Gold"; Deut Ärzteblatt Int 106:464; 2009.